Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





FENSULFOTHION								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 115-90-2; **Chemical Formula:** C11H17O4PS2
Previously, OSHA had no limit for fensulfothion. The ACGIH has a TLV-TWA of 0.1 mg/m3. The proposed PEL was 0.1 mg/m3 as an 8-hour TWA; NIOSH (Ex. 8-47, Table N1) concurs, and this limit is established by the final rule. Fensulfothion is a brown liquid at room temperature.
Fensulfothion has an acute oral LD(50) of 4 mg/kg in male rats and 1.8 mg/kg in female rats. Aerosol inhalation studies in rats have shown LC(50)s of 113 mg/m3 for a one-hour exposure and 29.5 mg/m3 for a four-hour exposure (Loeser and Kimmerle 1971, as cited in ACGIH 1986/Ex. 1-3, p. 266). This insecticide has been shown to have effects similar to those of the other thiophosphates, which cause cholinesterase inhibition. Dermal toxicity is high, with LD(50) values ranging between 14 and 30 mg/kg for male rats and between 3.5 and 3.0 mg/kg for females (NIOSH 1974d, as cited in ACGIH 1986/Ex. 1-3, p. 266). Tests of mice and rabbits have shown no embryotoxic, reproductive, or mutagenic effects. The no-effect dietary level in subchronic feeding studies is reported to be 1 ppm in rats and 2 ppm in dogs. The no-effect level for cholinesterase inhibition is reported as 1 ppm in the diet for both dogs and cats (ACGIH 1986/Ex. 1-3, p. 266).
In humans, dermal studies have shown irritation without cholinesterase effects from two-hour, twice-daily applications of a 5-percent granular formulation to the forearms of three subjects. Systemic absorption through the lungs has been demonstrated after inhalation of fensulfothion aerosols (ACGIH 1986/Ex. 1-3, p. 266). No comments, other than NIOSH’s, were received on this substance.
In the final rule, OSHA is establishing a PEL of 0.1 mg/m3 TWA for this previously unregulated substance to reduce the significant risks of metabolic effects and skin irritation. The Agency concludes that this limit will substantially reduce these risks, and that skin irritation and cholinesterase inhibition are material impairments of health.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue